Ameluz Red-Light PDT Now FDA-Approved for Superficial Basal Cell Skin Cancer

Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, is a clinic-applied photosensitising gel used with a Biofrontera red-light lamp (BF-RhodoLED or RhodoLED XL). On 9 September 2026, FDA approved supplemental NDA 208081/S-040 adding treatment of superficial basal cell carcinoma (sBCC) in adults. The Prescribing Information is Revised 09/2026. The same product was already labelled for lesion-directed and field-directed treatment of actinic keratoses (AKs) of mild-to-moderate severity on the face and scalp.

Distinct path — not this carton door (fact-only): Everyday sunscreen, cryotherapy, topical field creams, or excision/Mohs surgery alone are not this labelled Ameluz–lamp combination. The older AK-only US labelled use is a separate indicated use of the same gel — this article is the NEW sBCC door. Compounded aminolevulinic acid, other brand PDT gels, or daylight PDT protocols outside the US labelled BF-RhodoLED / RhodoLED XL combination are not this NDA carton. Today’s US labelled red-light PDT drug door for adult sBCC is Biofrontera Ameluz NDA 208081 with BF-RhodoLED or RhodoLED XL.

Distributed by Biofrontera Inc., 660 Main Street, 1st Floor, Woburn, MA 01801. Ameluz is administered only by a health care provider — not a home tube.

Where this is taking place

Commercial labelled door today: United States — FDA-labelled Ameluz for sBCC in adults, applied in clinic, occluded ~3 hours, then illuminated with BF-RhodoLED or RhodoLED XL. Suspected adverse reactions: Biofrontera 1-844-829-7434 or FDA MedWatch 1-800-332-1088 / www.fda.gov/medwatch. Practice reimbursement navigation (clinic-facing, not a patient DIY line): 1-844-4AMELUZ (1-844-426-3589) ext. 7 or reimbursement@bfinc.com (Biofrontera HCP access pages). This is a dermatology PDT clinic conversation — not a DIY gel and not a DIY import.

Honesty on labelling surfaces: The FDA approval letter (9 Sep 2026) and USPI (Revised 09/2026) define the sBCC indication and Trial 4 results. Some Biofrontera patient/HCP web pages retrieved for this draft still emphasised the AK indication only — treat the FDA letter + USPI PDF as authoritative for sBCC until website copy catches up, and ask the treating clinician for the current carton Prescribing Information.

Outside the United States: EMA/EC — Ameluz holds EU marketing authorisation for AK / field cancerisation and for superficial and/or nodular BCC unsuitable for surgical treatment (EU indication language differs from the US “sBCC in adults” sentence; first EU authorisation December 2011). Health Canada: Ameluz brand authorisation not confirmed on sources used here. Do not import on your own. A US tube is not a foreign carton.

Trial 4 — NCT03573401 (ClinicalTrials.gov: ACTIVE_NOT_RECRUITING) — Randomized, double-blind, vehicle-controlled Phase 3 study of Ameluz + BF-RhodoLED for sBCC at US sites. Label: 187 adults enrolled; efficacy table n=145 Ameluz / n=42 vehicle. Sponsor: Biofrontera Inc. Overall official / principal investigator listed on CT.gov: David M. Pariser, MD, Virginia Clinical Research, Inc. Honesty: Labelled commercial access is through a prescribing dermatology clinic with the correct lamp — an ACTIVE_NOT_RECRUITING pivotal record is not walk-in research enrolment.

The practical commercial door in the US is a dermatologist / Mohs / PDT clinic that confirms superficial BCC histology, rules out contraindications, stocks Ameluz, and operates BF-RhodoLED or RhodoLED XL.

Approval matrix

Access by country

• United States: Ask a dermatologist who offers Ameluz PDT with BF-RhodoLED or RhodoLED XL about labelled treatment for adult sBCC. Labelled 9 September 2026 (S-040). Path: confirm superficial BCC (histology) → check contraindications (porphyria / porphyrin or soybean-component hypersensitivity / photodermatoses) → clinic gel application + ~3-hour occlusion + red-light illumination → follow-up 4–6 weeks after each cycle; skin checks every 6–12 months. AE: Biofrontera 1-844-829-7434. HCP / clinic reimbursement questions (not a patient DIY line): 1-844-426-3589 ext. 7. No list price or copay dollars in this article. This is US labelled clinic supply, not a DIY import.

• Canada: Ameluz authorisation not confirmed. Ask the Canadian dermatology / skin-cancer clinic what legal paths exist in Canada when a Canadian Ameluz label does not yet exist.

• European Union: Ameluz is EU-authorised for certain BCC uses (superficial and/or nodular BCC unsuitable for surgery) as well as AK — ask the local dermatology centre how that EU door maps to your lesion and whether red-light Ameluz PDT is offered locally. A US tube / US lamp protocol is not automatically your country’s carton.

• United Kingdom / Australia / Japan / other countries: Confirm your local regulator’s current status with the treating centre. Do not import on your own.

• If your regulator has not authorised it: do not import on your own. Ask the local clinician about documented special-access / named-patient rules, referral to a centre in a labelled country, or waiting.

Who is eligible (from FDA USPI + Trial 4)

This is a clinic-administered labelled expansion conversation — not a home treatment, and not established as labelled for every BCC subtype.

United States (USPI Revised 09/2026 + Trial 4):

• Indication (sBCC): Treatment of superficial basal cell carcinoma (sBCC) in adults, in combination with PDT using BF-RhodoLED or RhodoLED XL.
• Regimen: Treat one or multiple sBCC lesions with Ameluz + PDT in two sessions spaced 1 to 2 weeks apart. Approximately 3 months after the initial treatment, retreat lesions that have not completely resolved with two additional sessions, spaced 1 to 2 weeks apart. Follow-up examination 4 to 6 weeks after each treatment cycle; routine skin examinations every 6 to 12 months.
• Application: ~1 mm thick lesion-directed layer; include ~10 mm of surrounding healthy skin for sBCC; application area ≤60 cm²; ≤6 g (3 tubes) at one time; dry ~10 minutes; occlusive dressing ~3 hours; then illuminate.
• Contraindications: Known hypersensitivity to porphyrins; known hypersensitivity to any component of Ameluz (includes soybean phosphatidylcholine); porphyria; photodermatoses.
• Warnings (highlights): Hypersensitivity (including severe courses); transient amnestic episodes; BF-RhodoLED / RhodoLED XL eye-injury risk (protective eyewear); ophthalmic adverse reactions; increased photosensitivity (~48 hours sun/intense light avoidance on treated sites); bleeding risk with coagulation disorders; mucous-membrane irritation.
• Most common application-site reactions in Trial 4 sBCC (Ameluz n=145, ≥1% and >vehicle): pain 95%, erythema 69%, pruritus 50%, edema 29%, paraesthesia 24%, scab 21%, induration 17%, exfoliation 17% (USPI Table 2).
• Pediatrics: Safety and effectiveness below age 18 not established for this use (sBCC / AK not generally pediatric conditions on label).
• Not a substitute for: appropriate surgical / Mohs decisions when the dermatologist judges surgery the better path for that lesion.

Not labelled on sources confirmed for this draft:

• Nodular, infiltrative, morpheaform, or other non-superficial BCC subtypes as the US labelled population (US sentence is superficial BCC in adults).
• Home self-application or use with a non–BF-RhodoLED / RhodoLED XL lamp under the US combination product labelling.
• Canadian Ameluz marketing authorisation (not confirmed here).
• Treating ACTIVE_NOT_RECRUITING research as open commercial trial recruitment.

How to access (United States)

1. Confirm histology-proven superficial basal cell carcinoma with a dermatologist (or dermatologic surgeon) who manages non-melanoma skin cancer.
2. Ask whether the clinic offers Ameluz with BF-RhodoLED or RhodoLED XL (clinic-administered combination — not a take-home gel).
3. Review contraindications, photosensitising medicines, coagulation issues, pregnancy status when relevant, and expected application-site pain during illumination.
4. Plan the two-session cycle (1–2 weeks apart), ~3-hour occlusion day logistics, 48-hour light avoidance after treatment, and 3-month reassessment for possible second cycle.
5. Clinics may use Biofrontera reimbursement support at 1-844-426-3589 ext. 7 for prior-auth / coding questions (HCP-facing).
6. Authorised is not funded — insurance, prior authorisation, and out-of-pocket paths vary; no prices in this article.

Evidence snapshot (labelled pivotal)

Trial 4 — NCT03573401 (USPI 14.2):

• Design: multicenter, randomized, double-blind, vehicle-controlled; Ameluz or vehicle + BF-RhodoLED; US sites.
• Population: 187 adults with ≥1 histologically confirmed sBCC; efficacy analysis n=145 Ameluz / n=42 vehicle; age 33–89 (mean 63); 95% Fitzpatrick I–III; all White in the reported trial population; 57% male; most had one lesion (48% neck/trunk, ~45% extremities).
• Regimen: ≥1 PDT cycle of two sessions 7–14 days apart; ~3-hour occlusion; up to one 2 g tube per session in the trial; second cycle if partial/non-responder at 12 weeks (62/145 Ameluz; 35/42 vehicle).
• Primary endpoint: Main Target Lesion composite clinical and histological complete response 12 weeks after start of last PDT cycle — 95/145 (66%) Ameluz vs 2/42 (5%) vehicle.
• Key secondaries (USPI Table 4): histological response 76% vs 19%; clinical response 83% vs 21%; subject complete clinical response 82% vs 21%; subject complete response 64% vs 5%.
• Honesty note from label: 26/119 (22%) Ameluz subjects who looked clinically clear still had histologically confirmed residual sBCC — histology matters.

CT.gov named status: ACTIVE_NOT_RECRUITING (retrieved 22 Sep 2026). Not walk-in enrolment.

How to talk with a doctor

Bring this page and ask a dermatologist / PDT clinic:

1. “I have histology-confirmed superficial BCC. Is labelled US Ameluz with BF-RhodoLED or RhodoLED XL a fit for this lesion?”
2. “Does this clinic stock Ameluz and operate the labelled Biofrontera red-light lamp?”
3. “What does the two-session schedule look like, and when would we decide on a second cycle at ~3 months?”
4. “How will we handle pain during illumination, 48-hour light avoidance, and follow-up exams?”
5. If outside the US: “Has our regulator authorised Ameluz for my BCC type, or what legal special-access options exist?”

Who is involved (from primary sources)

• Application holder / US distributor: Biofrontera Inc., 660 Main Street, 1st Floor, Woburn, MA 01801 (USPI; FDA letter addressed via Cardinal Health Regulatory Sciences for Biofrontera Inc.).
• FDA signatory (approval letter): Tatiana Oussova, MD, MPH, Deputy Director for Safety, Division of Dermatology and Dentistry, CDER (letter 09 Sep 2026).
• Pivotal program: Trial 4 — NCT03573401; sponsor Biofrontera Inc.
• Overall official / PI (CT.gov): David M. Pariser, MD — Virginia Clinical Research, Inc.
• AE contact: Biofrontera Inc. 1-844-829-7434; FDA MedWatch 1-800-332-1088.
• Practice reimbursement (HCP): 1-844-4AMELUZ (1-844-426-3589) ext. 7; reimbursement@bfinc.com (us.ameluz.com HCP access pages).

Names and roles above are limited to what appears on the primary sources cited. Contacts not listed on those sources are omitted.

Sources

• FDA approval letter NDA 208081/S-040, signed 09 Sep 2026 — appletter PDF
• FDA Prescribing Information Ameluz, Revised 09/2026 — label PDF
• ClinicalTrials.gov NCT03573401 (ACTIVE_NOT_RECRUITING; PI David M. Pariser, MD)
• Biofrontera HCP access / reimbursement pages (us.ameluz.com) — practice line 1-844-426-3589 ext. 7
• EMA Ameluz EPAR / product information (EU MA; AK + BCC unsuitable for surgery; PI update noted 03 Jun 2026 on EMA medicines page)
• Health Canada DPD API brand search for “Ameluz” — no product returned on retrieval for this draft

Authorized is not funded. Not medical advice.

Not medical advice. Status: Unpublished. Do not publish.